NCT06829641View on ClinicalTrials.gov

Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC

Not yet recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

August 9, 2025

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2026

Conditions
NSCLC Stage IIIB, NSCLC Stage IIIC
Interventions
PROCEDURE

Tislelizumab Combined with Chemotherapy,

Tislelizumab Combined with Chemotherapy as Induction Therapy

All Listed Sponsors
lead

West China Hospital

OTHER

NCT06829641 - Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC | Biotech Hunter | Biotech Hunter